Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31110604 | 1.00 | L3MBTL1 (0.63) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31110610 | 1.00 | L3MBTL1 (0.63) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31110588 | 0.95 | LMNA (0.64) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31110564 | 0.93 | L3MBTL1 (0.54) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31110599 | 0.88 | LMNA (0.56) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31110603 | 0.88 | LMNA (0.56) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31110612 | 0.88 | LMNA (0.56) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31110609 | 0.88 | LMNA (0.56) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31696214 | 0.85 | USP2 (0.52) | L3MBTL1LMNATDP1KMT2AALDH1A1 | |
| SCHEMBL31110569 | 0.83 | LMNA (0.62) | L3MBTL1LMNATDP1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472948-A2 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023147161-A2 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230242558-A1 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242558-A1 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | NAMPT, NNT, NAPRT | L3MBTL1 4427/4885LMNA 539/4885TDP1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.